Leap Therapeutics Stock Forecast, Price & News

+0.05 (+2.86 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume665,318 shs
Average Volume684,658 shs
Market Capitalization$107.41 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Leap Therapeutics logo

About Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.39 out of 5 stars

Medical Sector

752nd out of 2,099 stocks

Pharmaceutical Preparations Industry

373rd out of 830 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

Is Leap Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Leap Therapeutics stock.
View analyst ratings for Leap Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Leap Therapeutics?

Wall Street analysts have given Leap Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Leap Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Leap Therapeutics

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings results on Friday, May, 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. Leap Therapeutics had a negative trailing twelve-month return on equity of 59.46% and a negative net margin of 1,961.13%.
View Leap Therapeutics' earnings history

How has Leap Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Leap Therapeutics' stock was trading at $2.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LPTX shares have decreased by 10.4% and is now trading at $1.80.
View which stocks have been most impacted by COVID-19

What price target have analysts set for LPTX?

4 analysts have issued 12-month price objectives for Leap Therapeutics' stock. Their forecasts range from $3.50 to $8.00. On average, they anticipate Leap Therapeutics' share price to reach $4.88 in the next twelve months. This suggests a possible upside of 170.8% from the stock's current price.
View analysts' price targets for Leap Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the following people:
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec., Pres, CEO & Director (Age 52, Pay $865.24k)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 64, Pay $609.51k)
  • Dr. Cynthia A. Sirard, Chief Medical Officer (Age 51, Pay $617.04k)
  • Mr. Mark O'Mahony, Chief Manufacturing Officer (Age 50)
  • Ms. Christine M. Granfield, VP and Head of Regulatory Affairs & Quality (Age 53)
  • Dr. Jason S. Baum Ph.D., VP & Head of Translational Medicine
  • Dr. Walter Newman, Sr. Research Fellow (Age 75)

Who are some of Leap Therapeutics' key competitors?

What other stocks do shareholders of Leap Therapeutics own?

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Hillhouse Capital Advisors LTD. (5.99%), Platinum Investment Management Ltd. (1.53%), Opaleye Management Inc. (0.65%), Geode Capital Management LLC (0.59%), Silverarc Capital Management LLC (0.50%) and BlackRock Inc. (0.36%).
View institutional ownership trends for Leap Therapeutics

Which major investors are selling Leap Therapeutics stock?

LPTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Platinum Investment Management Ltd., Hillhouse Capital Advisors LTD., Golden Green Inc., Acadian Asset Management LLC, McAdam LLC, Millennium Management LLC, and Clear Harbor Asset Management LLC.
View insider buying and selling activity for Leap Therapeutics
or view top insider-selling stocks.

Which major investors are buying Leap Therapeutics stock?

LPTX stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Geode Capital Management LLC, Morgan Stanley, Silverarc Capital Management LLC, Barclays PLC, Virtu Financial LLC, D.A. Davidson & CO., and BlackRock Inc..
View insider buying and selling activity for Leap Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $1.80.

How much money does Leap Therapeutics make?

Leap Therapeutics has a market capitalization of $107.41 million and generates $1.50 million in revenue each year. The company earns $-27,510,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

How many employees does Leap Therapeutics have?

Leap Therapeutics employs 30 workers across the globe.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is

Where are Leap Therapeutics' headquarters?

Leap Therapeutics is headquartered at 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.